Quantcast
Last updated on April 16, 2014 at 17:34 EDT

Latest Precision Therapeutics Inc. Stories

2012-10-02 02:30:31

PHILADELPHIA, REHOVOT, Israel, and PITTSBURGH, Oct. 2, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, and Precision Therapeutics, Inc. (PTI), a life science company known for its expertise in the science of personalizing cancer therapy by advancing genomic testing and bioinformatics, today announced the commercial launch of the miRview(®) mets(2 )assay in the U.S. oncology market. miRview(®)...

2012-07-24 02:29:14

PHILADELPHIA and REHOVOT, Israel, July 24, 2012 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostic assays, announced today that it has entered into a co-marketing agreement for its miRview(®) mets(2) assay for the accurate identification of the tumor of origin in Cancers of Unknown or Uncertain Primary ("CUP") with Precision Therapeutics Inc., a life science company known for its expertise in the science of...

2012-01-24 12:05:00

PITTSBURGH, Jan. 24, 2012 /PRNewswire/ -- Precision Therapeutics, Inc. has recently expanded their BioSpeciFx® product to include 21 clinically-relevant biomarkers to help physicians with their treatment decisions. This enhances Precision's approach to personalizing cancer care by offering additional molecular markers, including the recently FDA-approved ALK-FISH test. By utilizing BioSpeciFx® results in combination with Precision Therapeutics' ChemoFx® in vitro drug response...

2011-06-06 16:39:00

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Dr. Bradley Monk of the Creighton University School of Medicine presented a new gynecologic cancer study at the 2011 American Society of Clinical Oncology (ASCO) Annual Symposium, June 5th in Chicago, Illinois. The study, titled, Acquired Drug Resistance in Gynecologic Cancer Detected by an In Vitro Assay, begins to answer the question of whether ChemoFx® Drug Response Marker test results taken in the primary setting can be...

2011-06-06 16:33:00

PITTSBURGH, June 6, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. demonstrated data supporting the utility of cell line-derived multi-gene predictors in the prediction of preoperative chemotherapy response in early stage breast cancer at the 2011 ASCO Annual Meeting on June 4, 2011 in Chicago, Illinois. The study, titled, Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response: A Validation Study on the NSABP B-27 Trial, combined the genomic...

2011-04-07 13:38:00

PITTSBURGH, April 7, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. announced that the launch of a new product line, BioSpeciFx®, will help further the personalization of cancer treatments. BioSpeciFx® is composed of carefully selected sets of well validated and clinically useful biomarker tests that identify critical molecular targets within a patient's cell. By using the information generated by BioSpeciFx® in combination with...

2011-01-19 16:00:00

PITTSBURGH, Jan. 19, 2011 /PRNewswire/ -- Precision Therapeutics, Inc. will present pancreatic cancer data based on Precision's ChemoFx® in-vitro chemosensitivity test at the 2011 American Society of Clinical Oncology (ASCO) GI Symposium, January 20-22 in San Francisco, California. The two studies accepted by the ASCO GI are titled, InVitro Sensitivity of 5 FU and Gemcitabine in Pancreatic Cancer and Pattern of In Vitro Chemotherapy Response in Pancreatic Cancer and...

2010-09-02 14:28:00

PITTSBURGH, Sept. 2 /PRNewswire/ -- Precision Therapeutics ranked first place as an industry leader in the health care division and third place across all industries on the Pittsburgh Business Times Top 100 list, which identifies the area's fastest-growing, privately held companies. With a growth rate of 847% since 2007, Precision has become an industry leader in personalized cancer therapy by recently hiring 100 new employees and raising $35 million in venture capital to provide...

2010-06-30 11:00:00

PITTSBURGH, June 30 /PRNewswire/ -- Precision Therapeutics, a life-science company known for their expertise in the science of individualizing cancer therapy through the use of a proprietary and unique live-tissue platform, continues to gain ground in novel genomic testing and bioinformatics research. Precision Therapeutics has recently recruited key scientific research experts, biostatisticians and medical specialists to support their development efforts. "I think Precision is...

2010-06-03 08:30:00

PITTSBURGH, June 3 /PRNewswire/ -- A study demonstrating the cost savings realized through the use of the ChemoFx® Drug Response Marker for assisting selection of treatment in recurrent ovarian cancer was published recently in the American Journal of Obstetrics and Gynecology (AJOG). This economic analysis of recurrent ovarian cancer patients studied the direct costs of chemotherapy for three groups; empiric, assay-assisted, and assay-adherent. This study demonstrated...